Novartis Gene Therapy Faces Tumor Probe, FDA Warns on GLP-1 Eye Risks
Novartis's gene therapy Zolgensma is under FDA investigation after nine patients developed tumors. Meanwhile, the FDA requires a safety warning for all GLP-1 weight loss drugs regarding a rare vision-threatening eye condition, as the agency faces a busy month of drug decisions.
Original image temporarily unavailable
This week in biotech brings several major regulatory and clinical updates. Novartis confirmed that nine patients receiving its spinal muscular atrophy gene therapy Zolgensma have developed tumors, prompting an FDA investigation. Additionally, Novartis and Ionis shared details from their failed cardiovascular trial for pelacarsen, casting doubt on targeting lipoprotein(a). In regulatory news, the FDA is ordering all 12 market-approved GLP-1 receptor agonists, including popular drugs from Novo Nordisk and Eli Lilly, to add labels warning of a rare eye disease that can cause blindness. Meanwhile, the FDA faces a stacked November schedule with decisions expected on therapies from Summit Therapeutics, Vertex, and Capricor Therapeutics.
View selection rationale
Importance 85/100
About this brief
- Content type
- Research summary
- Source type
- Publisher report
- Original source
- BioSpace Drug Development ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.
